Literature DB >> 12161900

Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.

Ali Arslantas1, Sevilhan Artan, Ulkü Oner, Ramazan Durmaz, Hamza Müslümanoğlu, Metin Ant Atasoy, Nurettin Başaran, Eşref Tel.   

Abstract

BACKGROUND: Meningiomas are common tumors of the central nervous system. Although most are benign tumors, approximately 10% show a histologic progression to a higher malignancy grade similar to atypical (GII) and anaplastic (GIII) meningiomas. Monosomy 22q12 is the most frequent genetic alteration detected in these tumors, but failure of detection of 22q mutations in about 40% of tumors which are indistinguishable from meningiomas with 22q deletions with respect to clinical and histopathologic features, makes it apparent that an alternative mechanism is responsible for the initiation of meningioma. Moreover, little is known about genetic alterations during malignant progression of meningioma.
PURPOSE: In order to determine the genetic pathways underlying the development of meningioma, 15 benign (WHO grade I), 7 atypical (WHO grade II) and 3 anaplastic (WHO grade III), sporadic meningiomas were screened by Comparative Genomic Hybridization (CGH).
RESULTS: Statistical analysis revealed a significant correlation between the number of chromosomal imbalances and the tumor grade; the numbers of total alterations detected per tumor were 2.20 (2.24 for GI, 10.00 (1.17 for GII and 14.66 (1.15 for GIII. The most frequent abnormality seen in benign tumors was loss on 22q (47%). The second alteration was 1p deletion (33%) and this abnormality was also the common aberration in three tumors without CGH detected 22q deletion. In GII, aberrations most commonly identified were losses on 1p (6/7 cases), 22q (5/7 cases), 10q (4/7 cases), 14q and 18q (3/7 cases) as well as gains on 15q and 17q (3/7 cases). In GIII, genomic loss on 1p was the most commonly observed abnormality (3/3). Losses on 9p, 10q, 14q, 15q, 18q and 22q as well as gains on 12q, 15q and 18p were the other genomic alterations detected by CGH. Combined 1p/14q deletions were encountered in 2/15 benign, 3/7 atypical and 2/3 anaplastic meningiomas. By CGH, DNA sequences on 17q21-qter were seen to be amplified in 1/7 GII and 2/3 GIII, whereas highly amplified DNA sequences on 12q13-qter, 20q and 22q11-q12 were seen in one GII, two GII/one GIII, and one GIII, respectively.
CONCLUSION: It was concluded that chromosomal deletion from 1p could play a major role in the initiation and progression of meningiomas and that 1p/14q deletions could be a primary focus of further detailed assessment of tumour genesis.

Entities:  

Mesh:

Year:  2002        PMID: 12161900

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  10 in total

1.  Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; M Hamza Müslümanoglu; Muhsin Ozdemir; Ramazan Durmaz; Didem Arslantas; Murat Vural; Erhan Cosan; Metin Ant Atasoy
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

2.  Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.

Authors:  Hong Wei Yang; Tae-Min Kim; Sydney S Song; Nihal Shrinath; Richard Park; Michel Kalamarides; Peter J Park; Peter M Black; Rona S Carroll; Mark D Johnson
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

3.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

4.  Methylation-specific multiplex ligation-dependent probe amplification in meningiomas.

Authors:  Christian Ewald; Thomas Hofmann; Susanne A Kuhn; Thomas Deufel; Christian Beetz; Rolf Kalff
Journal:  J Neurooncol       Date:  2008-09-02       Impact factor: 4.130

5.  Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.

Authors:  Sevim Akcaglar; Ismet Yavascaoglu; Hakan Vuruskan; Bulent Oktay
Journal:  Int Urol Nephrol       Date:  2007-12-12       Impact factor: 2.370

6.  Specific genes expressed in association with progesterone receptors in meningioma.

Authors:  Elizabeth B Claus; Peter J Park; Rona Carroll; Jennifer Chan; Peter M Black
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome.

Authors:  Darlene Gabeau-Lacet; David Engler; Sumeet Gupta; George A Scangas; Rebecca A Betensky; Fred G Barker; Jay S Loeffler; David N Louis; Gayatry Mohapatra
Journal:  J Neuropathol Exp Neurol       Date:  2009-10       Impact factor: 3.685

8.  'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors.

Authors:  Rachael Thomas; Shannon E Duke; Huixia J Wang; Tessa E Breen; Robert J Higgins; Keith E Linder; Peter Ellis; Cordelia F Langford; Peter J Dickinson; Natasha J Olby; Matthew Breen
Journal:  J Neurooncol       Date:  2009-03-31       Impact factor: 4.130

9.  First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.

Authors:  Ramita Dewan; Alexander Pemov; Amalia S Dutra; Evgenia D Pak; Nancy A Edwards; Abhik Ray-Chaudhury; Nancy F Hansen; Settara C Chandrasekharappa; James C Mullikin; Ashok R Asthagiri; John D Heiss; Douglas R Stewart; Anand V Germanwala
Journal:  BMC Cancer       Date:  2017-02-13       Impact factor: 4.430

10.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.